The observation that silencing PKCι leads to apoptosis in PRKCI-amplified ovarian cancer cells urged us to turn attention on those small molecules reported to inhibit atypical PKCs such as Aurothiomalate (ATM), Auranofin (ANF) and Oncrasin-1 as potential therapeutic agents for the subset of ovarian cancer patients with PRKCI amplification. This evidence concerns the gene PRKCI and ovarian carcinoma.